Figure S1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Christina V. Angeles(Memorial Sloan Kettering Cancer Center), Samuel Singer(Memorial Sloan Kettering Cancer Center), Rodrigo Gularte‐Mérida(Memorial Sloan Kettering Cancer Center), Penelope D. Ruiz(Memorial Sloan Kettering Cancer Center), David Shum(Hong Kong Polytechnic University), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Hakim Djaballah(High Throughput Biology (United States)), Bernadette Laxa(Memorial Sloan Kettering Cancer Center), Irina Ostrovnaya(Memorial Sloan Kettering Cancer Center), Jordan Rios(Memorial Sloan Kettering Cancer Center), Ana Velez, Tomoyo Okada(Memorial Sloan Kettering Cancer Center), Yawei Shen(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
|Nature Genetics|2013|818
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
|Nature Genetics|2010|725
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
|Oncogene|2001|700
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
|American Journal Of Pathology|2000|647